Kidney Disease News and Research

RSS

FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension

Medtronic, Inc., announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity Catheter System for the treatment of resistant hypertension, an especially dangerous disease affecting hundreds of millions of people worldwide.

From Medtronic 12 Jul 2011

Cardiology study looks at sodium and potassium in diet

A new study suggests that in addition to cutting the amount of sodium in their diets to improve heart health, Americans should also increase consumption of a key mineral found in many fruits and vegetables, potassium.

11 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

ASN President discusses latest information about diabetic nephropathy at ADA

ASN President Dr. Joseph V. Bonventre, MD, PhD, spoke at the American Diabetes Association's annual meeting, 71st Scientific Session, this June in San Diego. Dr. Bonventre was featured at a symposium entitled "New Concepts in Diagnosing and Treating Diabetic Nephropathy."

6 Jul 2011

Periodontal disease can affect woman's chance of conceiving

Professor Roger Hart told the annual meeting of the European Society of Human Reproduction and Embryology that the negative effect of gum disease on conception was of the same order of magnitude as the effect of obesity.

5 Jul 2011

Anti-inflammatory drugs may increase risk of atrial fibrillation

Commonly used painkillers to treat inflammation are linked to an increased risk of irregular heart rhythm, concludes a study published on bmj.com today.

5 Jul 2011

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

FDA directive on anemia drug in kidney disease patients

The U.S. Food and Drug Administration (FDA) has issued new warnings for anemia drugs for patients with kidney disease after studies suggested such drugs could increase stroke risks. The new warnings are the latest to hit the widely used medications since 2007, when the FDA first said they could cause fatal side effects.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

The University of Virginia Health System has received a $300,000 grant to study the "Call to Health" model, which uses text messages, stress reduction and other techniques to help African-American women manage type 2 diabetes.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Kidney Disease News and Research

FDA approves protocol for Medtronic's SYMPLICITY HTN-3 for treatment of hypertension

Cardiology study looks at sodium and potassium in diet

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

ASN President discusses latest information about diabetic nephropathy at ADA

Periodontal disease can affect woman's chance of conceiving

Anti-inflammatory drugs may increase risk of atrial fibrillation

Sorbent expands $36M Series B financing

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

FDA directive on anemia drug in kidney disease patients

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

UVA to study how the 'Call to Health' model helps African-American women manage diabetes

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News